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Many pneumonia etiology case-control studies exclude controls with respiratory illness from enrollment or analyses. Herein we ar-
gue that selecting controls regardless of respiratory symptoms provides the least biased estimates of pneumonia etiology. We review 3 
reasons investigators may choose to exclude controls with respiratory symptoms in light of epidemiologic principles of control selec-
tion and present data from the Pneumonia Etiology Research for Child Health (PERCH) study where relevant to assess their validity. 
We conclude that exclusion of controls with respiratory symptoms will result in biased estimates of etiology. Randomly selected 
community controls, with or without respiratory symptoms, as long as they do not meet the criteria for case-defining pneumonia, 
are most representative of the general population from which cases arose and the least subject to selection bias.
Keywords. PERCH; control selection; respiratory symptoms; pneumonia etiology; selection bias.
 
One of the greatest challenges of case-control studies is identi-
fication of a suitable control group. If the control group is not 
representative of the population giving rise to the cases, results 
are susceptible to bias. For controls to be representative of the 
target population, they should be selected independently of the 
exposure of interest and must satisfy the conditions that (1) 
they could have become a case, and (2) if they had become a 
case, there is no a priori condition or circumstance that would 
have excluded them from detection or enrollment as a case. For 
studies of hospitalized pneumonia, the question of representa-
tiveness of controls usually centers on the choice of community 
vs hospital controls. Potential biases can be introduced by the 
selection of either hospital or community controls; some studies 
have chosen to enroll both groups of controls to hedge against 
each set of biases [1]. For the Pneumonia Etiology Research for 
Child Health (PERCH) study, we made an a priori decision to 
enroll controls only from the community because we believed 
this was the most representative sample introducing the least 
bias in evaluating both pneumonia etiology and risk factors, the 
primary objectives of PERCH; our rationale has been described 
previously [2].
Regardless of whether enrolling hospital or community 
controls, many case-control studies that evaluate risk fac-
tors for pneumonia or vaccine effectiveness do not restrict 
enrollment of controls based on the presence of respira-
tory symptoms [1, 3–10]. In contrast, many case-control 
studies of pneumonia etiology restrict the control group to 
asymptomatic or healthy children at the time of enrollment 
[11–15]. Some case-control studies have also excluded from 
analysis any controls who developed respiratory symptoms in 
the subsequent weeks following enrollment [11]. Only a few 
case-control studies have permitted children with respiratory 
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illness to be included as controls [16–19]. When designing 
PERCH, we considered this question and decided that the 
optimal set of controls would include those without and with 
respiratory symptoms (excluding those with case-defining 
illnesses, namely severe and very severe pneumonia).
There are several reasons why investigators might choose 
to exclude controls with respiratory symptoms in pneumo-
nia etiology studies. The first is to prevent misclassification 
of cases as controls. Most respiratory symptoms can be pres-
ent in children whose illness severity ranges from upper res-
piratory tract infection (URTI) to very severe pneumonia. 
Drawing a line on that spectrum to firmly distinguish upper 
vs lower respiratory tract infections can lead to misclassifica-
tion. A second reason for excluding controls with respiratory 
symptoms could be that, although controls may not meet all of 
the case-defining criteria at the time of screening, they may be 
in an intermediate state and develop case-defining pneumo-
nia soon thereafter. Some investigators might consider that if 
these controls are already on the pathway to pneumonia, they 
should be thought of as “precases” and excluded from the con-
trol group. A  third reason stems from the fact that diagnos-
tic specimens from the site of primary infection (ie, the lung) 
are rarely obtained, so specimens from the upper respiratory 
tract are used to infer what is infecting the lung. Many of 
the same pathogens causing URTI (or colonization) can also 
cause pneumonia. It can be argued that controls with URTI 
will have elevated prevalence of some pathogens in the upper 
respiratory tract, and their inclusion as controls will underes-
timate the role of these pathogens in causing pneumonia in a 
case-control analysis.
In this article, we argue that these reasons do not justify the 
exclusion of controls with respiratory symptoms from pneumo-
nia etiology studies such as PERCH. Where relevant, we pres-
ent data from PERCH which support the decision to include all 
controls in the main PERCH etiology analysis.
OVERVIEW OF THE PERCH STUDY
Identification and selection methods of cases and controls for 
the PERCH study have been described previously [2]. In brief, 
cases were hospitalized children aged 1–59 months with World 
Health Organization (WHO)–defined severe or very severe 
pneumonia enrolled at 9 sites in 7 countries: Bangladesh, The 
Gambia, Kenya, Mali, South Africa, Thailand, and Zambia. 
Exclusion criteria for cases were hospitalization within the 
previous 14 days, having been discharged as a PERCH case 
within the past 30 days, or resolution of lower chest wall 
indrawing following bronchodilator therapy for those with 
wheeze. Details about case definitions are provided elsewhere 
[20].
Controls were children aged 1–59 months living in the catch-
ment area for cases; they were randomly selected from the 
community year round, and frequency matched to cases within 
the following age groups: 1 to <6  months, 6 to <12  months, 
12 to <24  months, and 24 to <60  months. Potential controls 
were excluded only if they met the case definition of severe or 
very severe pneumonia, were hospitalized within the previous 
14 days, or were discharged as a PERCH case within the past 
30 days. The latter 2 criteria—also applied to cases to prevent (1) 
enrollment of nosocomial pneumonia cases and (2) reenroll-
ment of cases for the same pneumonia episode—ensured that 
controls were representative of the population at risk of becom-
ing a case.
Study staff trained on standardized clinical assessments 
examined potential case and control participants [21]. For 
controls, a clinical history of fever, cough, difficulty breathing, 
wheeze, inability to eat, runny nose, ear discharge, vomiting, 
diarrhea, abnormal sleepiness, and any other symptoms or signs 
reported by the guardian or study staff was collected. During 
clinical examination, children were assessed for the presence 
of cough, fever, rash, tachypnea, and the case-defining signs of 
severe and very severe pneumonia.
The institutional review board or ethical review commit-
tee approved the study protocol at each of the 7 institutions 
and at the Johns Hopkins Bloomberg School of Public Health. 
Parents or guardians of participants provided written informed 
consent.
CONTROLS WITH RESPIRATORY SYMPTOMS 
IN PERCH
Symptoms of respiratory illness were common among controls 
in PERCH (Figure 1A). Among 5102 human immunodefi-
ciency virus (HIV)–negative controls, 1683 (33.0%) had at least 
1 respiratory symptom (runny nose, cough, tachypnea, diffi-
culty breathing, wheeze, ear discharge, sore throat, or fever); 
the most common were runny nose (17.0%), cough (16.4%), 
tachypnea (11.3%), and fever (5.3%). Of those with respiratory 
symptoms, 676 (40.2%) had >1 symptom (Figure 1B). The prev-
alence of respiratory symptoms among controls varied by site; 
the percentage of controls with at least 1 symptom ranged from 
14.5% in South Africa to 52.0% in Mali. To exclude controls 
with these common respiratory symptoms could lead to a large 
percentage of the general population of children being excluded 
as controls in some sites, calling into question the representa-
tiveness of the selected control population. Moreover, the var-
iability of respiratory symptom prevalence among controls by 
site could lead to site differences in the representativeness of the 
control populations.
There is no standard definition of respiratory illness that 
can be easily applied to a control group. Should it be based on 
the presence of a single symptom or sign or require more than 
one, and if so which ones? Case-control studies of pneumonia 
have used various definitions of respiratory illness [11–19]. For 
example, tachypnea along with cough or difficulty breathing, 
is used to define nonsevere pneumonia in WHO clinical case 
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management guidelines [22] because it is a sensitive measure 
that can be used to identify and treat the majority of children 
presenting with nonsevere pneumonia. Yet, tachypnea, which 
can also be caused by many other conditions, for example, fever 
alone (due to a nonrespiratory illness) or agitation, can have low 
specificity [23] and, thus, low positive predictive value for pneu-
monia, particularly among randomly selected children in the 
community where expected pneumonia prevalence is low. In 
the case of PERCH, 10.3% of controls without any other respira-
tory symptom had tachypnea. Therefore, defining the presence 
of respiratory illness in a population of controls with respiratory 
symptoms can be challenging.
POTENTIAL MISCLASSIFICATION OF CASES AS 
CONTROLS
In pneumonia etiology studies, case definitions are often based 
on a constellation of symptoms, the identification of which relies 
on imperfect measurements. Because the symptoms of URTI 
and nonsevere pneumonia overlap with those of severe/very 
severe pneumonia, it is possible that children with respiratory 
symptoms enrolled as controls may have been cases who were 
missed due to errors in observation of case-defining symptoms 
and signs. Such differential misclassification can lead to results 
biased toward the null.
While it is possible that children with respiratory symptoms 
who were enrolled as controls did, in fact, have severe or very 
severe pneumonia, we believe this was a rare event in PERCH 
if it occurred. First, study staff at all sites underwent standard-
ized training in the identification of PERCH cases and controls, 
as described elsewhere in this supplement [21]. Clinical stand-
ardization of health-worker personnel involved in study enroll-
ment was achieved and maintained through on-site initial and 
refresher trainings, the development and use of a training web-
site and training materials, and intermittent evaluations and 
competency assessments throughout the study. Every poten-
tial control underwent a standardized clinical examination 
to ensure they did not meet the case definition at the time of 
enrollment. Second, we sought evidence in the PERCH data for 
case-control misclassification. If controls with respiratory symp-
toms had truly been cases of severe or very severe pneumonia 
Figure 1. A, Distribution of respiratory symptoms among human immunodeficiency virus (HIV)–negative controls in the Pneumonia Etiology Research for Child Health 
(PERCH) Study. *Observed or reported. Clinical history recorded information on presence/absence of runny nose, cough, fever, ear discharge, difficulty breathing, wheeze, 
and sore throat as reported by guardian or study staff; clinical examination included assessment of cough, respiratory rate, and temperature by trained examiner. Tachypnea 
was defined as a respiratory rate ≥60 breaths per minute on clinical examination for children 1–2 months of age, ≥50 for children 2–11 months, and ≥40 for children 
12–59 months. Fever on clinical examination was defined as temperature ≥38°C. B, Number of symptoms present among 1683 HIV-negative controls with any respiratory 
symptom. Respiratory symptoms (observed or reported) include runny nose, cough, tachypnea, fever, ear discharge, difficulty breathing, wheeze, and sore throat.
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during enrollment, it is possible that they sought care at a hos-
pital shortly thereafter. Four of the 9 study sites (Kilifi, Kenya; Sa 
Kaeo and Nakhon Phanom, Thailand; and Matlab, Bangladesh) 
were smaller rural sites where the study hospital served as the 
main referral hospital for the entire catchment area and where 
screening for PERCH occurred 24 hours a day, 7 days a week. 
Most cases of severe or very severe pneumonia seeking care 
would have presented to the study hospital and been identified 
by PERCH, though this may be less true of fatal cases at the 
Kenya site where a substantial number of child deaths occur 
outside of the main hospital at home or a closer health facility 
[24]. At these sites, we reviewed all enrolled PERCH cases to 
assess if they had been previously enrolled as a control. For all 
children enrolled both as a control and subsequently as a case, 
we reviewed time between enrollments to determine if the res-
piratory illness present during control enrollment was likely 
part of the same case-defining illness (ie, severe or very severe 
pneumonia). Of all 1942 controls enrolled at these 4 sites, 17 
(0.9%) were subsequently enrolled as a PERCH case: 6 (0.3%) 
had at least 1 respiratory symptom or sign and 11 (0.6%) had no 
reported or observed respiratory symptoms or signs at the time 
of control enrollment. For the 6 controls with respiratory symp-
toms, the time between enrollment as a control and the reported 
first appearance of symptoms associated with the severe or very 
severe pneumonia episode ranged from 66 to 269 days (Table 1). 
For these children, sufficient time had passed between control 
and case enrollment to conclude that the illness present at con-
trol enrollment was not part of the same illness that resulted in 
later enrollment as a case.
We can also show in these 4 sites that the risk of subsequently 
developing severe or very severe pneumonia and being enrolled 
in PERCH was not different between those with and without res-
piratory symptoms. Among controls with at least 1 respiratory 
symptom (n = 758), 6 were subsequently enrolled as a PERCH 
case (0.8% risk), while among those with no symptoms (n = 1184), 
11 were subsequently enrolled as a PERCH case (0.9% risk; rela-
tive risk, 0.9 [95% confidence interval {CI}, .3–2.3]). One would 
expect an excess risk of subsequent enrollment as a case among 
controls with respiratory symptoms if there were significant mis-
classification at enrollment among these controls.
We have less confidence that we would have detected misclas-
sification of controls based on subsequent enrollment as PERCH 
cases in the more urban sites (ie, Bamako, Mali; Lusaka, Zambia; 
Soweto, South Africa; and Dhaka, Bangladesh). In these sites, 
hospitalizations for pneumonia might have occurred at clini-
cal facilities other than the PERCH hospital. Additionally, con-
trols could have presented later as cases during nonenrollment 
hours at the sites without 24/7 enrollment (Mali, South Africa, 
The Gambia). Despite these limitations, we found no evidence 
of controls with respiratory symptoms being later enrolled as 
a case at the study hospital, except at The Gambia site where 3 
children were enrolled as cases 50, 81, and 230 days after being 
enrolled as a symptomatic control, again a sufficient amount of 
time to conclude that this was likely a separate illness.
We cannot claim with certainty that no controls with respira-
tory symptoms had severe or very severe pneumonia at the time 
of enrollment. In all sites, controls who subsequently developed 
severe pneumonia could have been hospitalized elsewhere. 
Moreover, in both urban and rural sites in low-income settings, 
children still die at home, so a control child who later developed 
fatal severe pneumonia could have been missed.
UPPER RESPIRATORY TRACT INFECTION AS AN 
INTERMEDIATE CONDITION ON THE CAUSAL 
PATHWAY TO PNEUMONIA
Slightly different than the argument about misclassification 
(which could be summarized, “Was a control actually a case and 
we missed it?”) is the question about whether controls should 
be excluded if they have an intermediate condition for the out-
come in question. For PERCH, this question can be rephrased 
Table 1. Characteristics of Pneumonia Etiology Research for Child Health (PERCH) Controls With Any Respiratory Symptom Subsequently Enrolled as 
PERCH Cases at 4 Study Sites—Kilifi, Kenya; Nakhon Phanom and Sa Kaeoa, Thailand; and Matlab, Bangladesh
Site Age, mo
Symptoms Present at 
Control Enrollment
Days Between 
Enrollment as Control 
and as Case
Duration of Longest 
Symptom at Time of 
Case Enrollment, d
Days Between Control 
Symptoms and Case 
Symptoms
Chest Radiograph Result 
During Hospitalization as 
a Caseb
Kilifi, Kenya 4 Cough, runny nose 223 14 209 Normal
Nakhon Phanom, 
Thailand
9 Rashc, tachypneac,d 207 7 200 Abnormal
Nakhon Phanom, 
Thailand
5 Coughc, runny nose 271 2 269 Normal
Matlab, Bangladesh 16 Cough, tachypneac,d 74 4 70 Uninterpretable
Matlab, Bangladesh 5 Cough 72 1 71 Abnormal
Matlab, Bangladesh 19 Coughc, runny nose 69 3 66 Abnormal
aNo PERCH controls were later enrolled as cases in Sa Kaeo, Thailand.
bAbnormal chest radiograph result: presence of alveolar consolidation and/or other infiltrate.
cSymptom observed or measured by PERCH staff upon clinical examination at enrollment. All other symptoms reported by parent or guardian.
d Tachypnea was defined as a respiratory rate ≥60 breaths per minute on clinical examination for children 1–2 months of age, ≥50 for children 2–11 months, and ≥40 for children 12–59 
months.
Downloaded from https://academic.oup.com/cid/article-abstract/64/suppl_3/S205/3858210
by London School of Hygiene & Tropical Medicine user
on 26 January 2018
Choosing a Control Group in Pneumonia Etiology Studies • CID 2017:64 (Suppl 3) • S209
as “If upper respiratory tract infection is on the causal chain 
or is an intermediate state on the path to severe or very severe 
pneumonia, then should controls with respiratory symptoms be 
excluded?” The similar risk of later being enrolled as a PERCH 
case observed for controls with vs without respiratory symp-
toms suggests that URTI is not on the causal pathway in pneu-
monia. However, in considering this question, we followed the 
epidemiologic rationale laid out by Charles Poole in his discus-
sion of whether to exclude controls with intermediate states in 
case-control studies [25]. Poole argues that case-control studies 
are efficient means to mimic cohort studies and as such the con-
trols need not be purged of persons in an intermediate state of 
the disease condition lest they deviate from the full cohort of 
persons from which the cases derived. The control group is only 
valid if it accurately reflects the exposure distribution among 
the population at risk for the outcome, regardless of intermedi-
ate states; a bias away from the null results when persons with 
the intermediate condition are excluded.
A population of children in a low-income country will have 
a substantial prevalence of the intermediate condition of URTI, 
as shown for the PERCH sites, which, if excluded, will create an 
overestimation of the association between the exposure (ie, the 
pathogen in the nasopharynx) and the disease (ie, severe or very 
severe pneumonia). We adapted Poole’s figure of a hypothetical 
cohort in which the exposure causes disease only through an 
intermediate condition to illustrate the potential bias (Figure 2). 
Here, the exposure, pathogen X in the nasopharynx, causes 
pneumonia only through URTI. Pathogen X represents a highly 
prevalent pathogen in the community (20%), which increases 
the risk of pneumonia by 50% (risk ratio = 1.5) among those 
exposed to it. A case-control study that enrolls all cases and a 
random sample of 100 controls regardless of respiratory symp-
toms produces an odds ratio that accurately represents the 
true risk ratio. A case-control study that enrolls all cases, but 
excludes controls with respiratory symptoms and enrolls a ran-
dom sample of healthy controls, overestimates the odds ratio 
by 20%, the attributable fraction by 33%, and the population 
attributable fraction by 33%. This theoretical phenomenon is 
illustrated by real-world data from a case-control pneumonia 
etiology study in Kenya in which the adjusted odds ratio for res-
piratory syncytial virus A infection was 12.5 (95% CI, 3.1–51.5) 
when the analysis was restricted to controls without respiratory 
symptoms, compared with 3.8 (95% CI, 2.2–6.6) when all con-
trols were included in the analysis [16]. A recent meta-analysis 
of case-control studies of the etiology of acute lower respiratory 
infection also showed that when using only controls without 
respiratory symptoms, the attributable fraction in the exposed 
for most respiratory viruses was higher than when including all 
controls [14]. Of note, Poole also shows a scenario in which dis-
ease can occur among persons without the intermediate condi-
tion (ie, in our example, controls without URTI could develop 
pneumonia), which results numerically in a similar bias.
CAN A PATHOGEN IN THE UPPER RESPIRATORY 
TRACT OF A CASE CAUSE RESPIRATORY ILLNESS 
UNRELATED TO THE PNEUMONIA EPISODE?
Among patients with pneumonia, a pathogen detected in the 
nasopharynx/oropharynx might be the cause of the pneumo-
nia, might be involved in the causal chain of pneumonia, or 
might represent a concurrent URTI unrelated to the pneu-
monic process. As to the first 2 possibilities, there is general 
acceptance that these can occur; however, there are few data 
to resolve whether the third scenario occurs. A  case-control 
study like PERCH, which is cross-sectional in nature and has 
few specimens from the lung, is unable to answer this question 
definitively, and the progression from URTI to pneumonia is 
likely a complex interplay between pathogens and risk fac-
tors (eg, malnutrition, comorbid illnesses, smoke exposure) 
[26]. However, to exclude controls with respiratory symptoms 
would dictate that detection of these pathogens in pneumonia 
cases, beyond the prevalence observed in asymptomatic con-
trols, would always be indicative of a causal role in pneumonia. 
This seems unlikely to be true for most pathogens detected in 
the upper respiratory tract of pneumonia cases. As an exam-
ple from PERCH, we present the upper respiratory tract poly-
merase chain reaction (PCR) prevalence of rhinovirus, a virus 
Figure 2. Depiction of realistic, hypothetical cohort in which pathogen X causes 
pneumonia solely through upper respiratory tract infection (URTI): comparison of 
a case-control study enrolling controls with and without URTI to a case-control 
study enrolling only controls without URTI. *The proportion of children that go on 
to develop URTI. **The proportion of children that go on to develop pneumonia.
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thought to cause both URTI and, less commonly, pneumonia 
(Figure 3). Rhinovirus nasopharyngeal or oropharyngeal prev-
alence was higher in cases than controls in some sites and lower 
in cases than controls at other sites. However, rhinovirus had 
higher prevalence among controls with respiratory symptoms 
compared to asymptomatic controls at 6 of the 9 PERCH sites. 
The most notable difference was found at the Thailand sites 
where 20% of controls with respiratory symptoms tested pos-
itive for rhinovirus on nasopharyngeal or oropharyngeal PCR 
compared with 9% of asymptomatic controls. The outcome 
of a case-control analysis that included or excluded controls 
with respiratory symptoms would give very different results in 
Thailand. The high prevalence of rhinovirus in controls, both 
with and without respiratory symptoms, suggests that rhino-
virus detection among cases constitutes a mixture of clinical 
states, including asymptomatic infection, URTI, and some in 
which rhinovirus is perhaps playing a causal role in pneumonia. 
Restricting the control group to children without respiratory 
symptoms would underestimate the prevalence of rhinovirus 
in the population from which the cases arose at most sites and 
overestimate the odds ratio of rhinovirus’ association with case 
status, consequently overestimating the etiology of rhinovirus 
as a cause of pneumonia.
Added to these biologic and interpretive reasons for inclusion 
of controls with upper respiratory symptoms are epidemiologi-
cal principles that favor the inclusion of controls with respiratory 
symptoms. While the prevalence of exposures need not be similar 
in cases and controls, restrictions to subsets of the general popu-
lation based on potential confounders or effect modifiers should 
be. For example, if the cases are restricted to girls, so should be the 
controls. Likewise, if the cases are not restricted in terms of res-
piratory symptoms, then the controls should not be either. Lack 
of such a restriction based on respiratory symptoms holds to the 
concept that case-control studies should mimic cohort studies as 
closely as possible, and one would not limit a cohort to only those 
children who do not develop respiratory illness.
CONCLUSIONS
In summary, the PERCH study was designed to enroll controls, 
regardless of respiratory symptoms, as long as they did not 
meet the case definition of severe or very severe pneumonia. 
We have provided explanations and data to support this deci-
sion. We found no evidence to suggest that controls with res-
piratory symptoms were misclassified cases. We showed that as 
case-control studies are meant to mimic cohort studies, exclu-
sion of controls with respiratory symptoms, some of whom 
might be in an intermediate state (ie, URTI) between health and 
disease (ie, severe and very severe pneumonia), can bias results 
away from the null. This decision also acknowledges that the 
presence of a pathogen in the upper respiratory tract of a pneu-
monia patient might be unrelated to the pneumonia episode. 
The sequence and synergy of multiple respiratory tract infec-
tions and their interplay with host factors in causing pneumo-
nia is complicated, and a cross-sectional, case-control study like 
PERCH, regardless of which control group is used in the analy-
sis, is not optimally designed to address this issue. By including 
all controls, regardless of respiratory symptoms, we aimed to 
uphold the epidemiological principle that the control group be 
representative of the target population from which cases arose 
to minimize bias in the case-control results.
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